Media headlines about Iradimed (NASDAQ:IRMD) have been trending somewhat positive on Thursday, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Iradimed earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned media headlines about the medical equipment provider an impact score of 47.3674941739415 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Iradimed stock opened at $14.35 on Thursday. The company has a market capitalization of $154.30, a P/E ratio of 287.00 and a beta of 1.55. Iradimed has a twelve month low of $7.85 and a twelve month high of $15.85.
Iradimed (NASDAQ:IRMD) last announced its earnings results on Tuesday, February 6th. The medical equipment provider reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.04. The company had revenue of $6.70 million for the quarter, compared to analyst estimates of $6.72 million. Iradimed had a return on equity of 3.03% and a net margin of 2.17%. The firm’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.11 earnings per share. research analysts expect that Iradimed will post 0.25 EPS for the current fiscal year.
In other Iradimed news, insider Louis S. Waldman sold 30,000 shares of the business’s stock in a transaction that occurred on Friday, March 16th. The stock was sold at an average price of $13.83, for a total value of $414,900.00. Following the sale, the insider now owns 5,221 shares of the company’s stock, valued at $72,206.43. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 60.10% of the stock is owned by insiders.
Iradimed Company Profile
IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.
Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.